Biggest changeThese non-GAAP measures may not be comparable to similarly titled measures used by other companies. 24 Index Twelve Months Ended December 31, (In thousands except per share amounts) 2023 2022 % Change Operating Income (GAAP) $ 155,023 $ 196,751 (21.2 )% Portfolio optimization plan costs – Cost of products sold 3,135 - Divestiture & other related income – Selling and administrative expenses - (2,532 ) Portfolio optimization plan costs – Selling and administrative expenses 24,706 - Adjusted operating income $ 182,864 $ 194,219 (5.8 )% Net Earnings (GAAP) $ 93,394 $ 140,887 (33.7 )% Divestiture & other related income, before tax - (2,532 ) Tax impact of divestiture & other related income (1) - 636 Portfolio optimization plan costs, before tax 27,841 Tax impact of portfolio optimization plan costs (1) (415 ) Adjusted net earnings $ 120,820 $ 138,991 (13.1 )% Diluted Earnings Per Share (GAAP) $ 2.21 $ 3.34 (33.8 )% Divestiture & other related income, net of tax - (0.04 ) Portfolio optimization plan costs, net of tax 0.65 - Adjusted diluted earnings per share $ 2.86 $ 3.29 (13.1 )% (1) Tax impact adjustments were determined based on the nature of the underlying non-GAAP adjustments and their relevant jurisdictional tax rates.
Biggest changeThese non-GAAP measures may not be comparable to similarly titled measures used by other companies. 24 Index Twelve Months Ended December 31, (In thousands except per share amounts) 2024 2023 % Change Operating Income (GAAP) $ 191,579 $ 155,023 23.6 % Portfolio Optimization Plan costs – Cost of products sold 1,362 3,135 Portfolio Optimization Plan costs – Selling and administrative expenses 5,269 24,706 Adjusted operating income $ 198,210 $ 182,864 8.4 % Net Earnings (GAAP) $ 124,666 $ 93,394 33.5 % Portfolio Optimization Plan costs, before tax 6,631 27,841 Tax impact of Portfolio Optimization Plan costs (1) (4,156 ) (415 ) Adjusted net earnings $ 127,141 $ 120,820 5.2 % Diluted Earnings Per Share (GAAP) $ 2.94 $ 2.21 33.0 % Portfolio Optimization Plan costs, net of tax 0.06 0.65 Adjusted diluted earnings per share $ 3.00 $ 2.86 4.9 % Operating Income (GAAP) $ 191,579 $ 155,023 23.6 % Depreciation and amortization 60,329 57,820 Share-based compensation expense 10,084 8,933 Portfolio Optimization Plan costs, before tax 6,631 27,841 Adjusted EBITDA $ 268,623 $ 249,617 7.6 % (1) Tax impact adjustments were determined based on the nature of the underlying non-GAAP adjustments and their relevant jurisdictional tax rates.
CRITICAL ACCOUNTING POLICIES In preparing the financial statements in accordance with accounting principles generally accepted in the U.S., management is required to make estimates and assumptions that have an impact on the asset, liability, revenue, and expense amounts reported. These estimates can also affect supplemental information disclosures of the Company, including information about contingencies, risk, and financial condition.
CRITICAL ACCOUNTING ESTIMATES In preparing the financial statements in accordance with accounting principles generally accepted in the U.S., management is required to make estimates and assumptions that have an impact on the asset, liability, revenue, and expense amounts reported. These estimates can also affect supplemental information disclosures of the Company, including information about contingencies, risk, and financial condition.
Changes in estimates of future cash flows caused by items such as unforeseen events or changes in market conditions could negatively affect the reporting units’ fair value and result in an impairment charge. Income Taxes The Company estimates its income tax expense in each of the taxing jurisdictions in which it operates.
Changes in estimates of future cash flows caused by items such as unforeseen events or changes in market conditions could negatively affect the reporting units’ fair value and result in an impairment charge. 27 Index Income Taxes The Company estimates its income tax expense in each of the taxing jurisdictions in which it operates.
Goodwill Valuation The Company reviews the carrying value of goodwill annually utilizing several valuation methodologies, including a discounted cash flow model. The Company completed its annual goodwill impairment test under Accounting Standards Codification (ASC) 350, Intangibles – Goodwill and Other , in the third quarter of 2023.
Goodwill Valuation The Company reviews the carrying value of goodwill annually utilizing several valuation methodologies, including a discounted cash flow model. The Company completed its annual goodwill impairment test under Accounting Standards Codification (ASC) 350, Intangibles – Goodwill and Other , in the third quarter of 2024.
Management believes the Company’s most critical accounting estimates and assumptions are in the following areas: 27 Index Revenue Recognition The Company recognizes revenue at the transfer of control of its products to the Company’s customers in an amount reflecting the consideration to which the Company expects to be entitled.
Management believes the Company’s most critical accounting estimates and assumptions are in the following areas: Revenue Recognition The Company recognizes revenue at the transfer of control of its products to the Company’s customers in an amount reflecting the consideration to which the Company expects to be entitled.
Segment performance is evaluated on operating income before any applicable divestiture & other related income, share-based compensation, acquisition, restructuring and other costs, including the portfolio optimization plan costs, and other costs (which are reported in Corporate & Other), interest expense, and income taxes.
Segment performance is evaluated on operating income before any applicable share-based compensation, acquisition, restructuring and other costs, including the Portfolio Optimization Plan costs, and other costs (which are reported in Corporate & Other), interest expense, and income taxes.
LIQUIDITY AND FINANCIAL POSITION Financial Condition The Company’s financial position remains strong. The Company is in compliance with its loan covenants calculated in accordance with applicable agreements as of December 31, 2023.
LIQUIDITY AND FINANCIAL POSITION Financial Condition The Company’s financial position remains strong. The Company is in compliance with its loan covenants calculated in accordance with applicable agreements as of December 31, 2024.
For a discussion of the year ended December 31, 2022, compared to the year ended December 31, 2021, please refer to Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on February 17, 2023, which is incorporated herein by reference.
For a discussion of the year ended December 31, 2023, compared to the year ended December 31, 2022, please refer to Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on February 22, 2024, which is incorporated herein by reference.
The Company’s contractual obligations consist primarily of operational commitments, which we expect to continue to be able to satisfy through cash generated from operations, and debt. The Company has various series of notes outstanding that mature from 2024 through 2029, with approximately $82 million coming due in 2024.
The Company’s contractual obligations consist primarily of operational commitments, which we expect to continue to be able to satisfy through cash generated from operations, and debt. The Company has various series of notes outstanding that mature from 2025 through 2029, with approximately $56 million coming due in 2025.
This section generally discusses the results of our operations for the year ended December 31, 2023, compared to the year ended December 31, 2022.
This section generally discusses the results of our operations for the year ended December 31, 2024, compared to the year ended December 31, 2023.
NEW PRONOUNCEMENTS Refer to the “ Recently Issued Accounting Pronouncements ” section within Note 1, “ Summary of Significant Accounting Policies ,” in the Notes to Consolidated Financial Statements included in this report for additional details. 28 Index
NEW PRONOUNCEMENTS Refer to the “ Recently Adopted Accounting Pronouncements ” and “ Recently Issued Accounting Pronouncements ” section within Note 1, “ Summary of Significant Accounting Policies ,” in the Notes to Consolidated Financial Statements included in this report for additional details.
See Note 11, Income Taxes , in the Notes to Consolidated Financial Statements included in this report for additional information. 2023 2022 Rate before portfolio optimization plan and discrete items 25.5 % 25.8 % Portfolio optimization plan impact 4.7 % - Discrete items (2.1 %) (3.1 %) Reported effective tax rate 28.1 % 22.7 % The 2024 effective income tax rate is estimated to be between 24% and 25%.
See Note 11, Income Taxes , in the Notes to Consolidated Financial Statements included in this report for additional information. 2024 2023 Rate before Portfolio Optimization Plan and discrete items 25.2 % 25.5 % Portfolio Optimization Plan impact 0.3 % 4.7 % Discrete items (2.1 %) (2.1 %) Reported effective tax rate 23.4 % 28.1 % The 2025 effective income tax rate is estimated to be between 24% and 26%.
NON-GAAP FINANCIAL MEASURES Within the following tables, the Company reports certain non-GAAP financial measures, including: (1) adjusted operating income, adjusted net earnings, and adjusted diluted earnings per share, which exclude the divestiture & other related income and restructuring and other costs, including the portfolio optimization plan costs and (2) percentage changes in revenue, operating income, and diluted earnings per share on an adjusted local currency basis, which eliminate the effects that result from translating its international operations into U.S. dollars, the divestiture & other related income, and restructuring and other costs, including the portfolio optimization plan costs.
NON-GAAP FINANCIAL MEASURES Within the following tables, the Company reports certain non-GAAP financial measures, including: (1) adjusted operating income, adjusted net earnings, and adjusted diluted earnings per share, which exclude restructuring and other costs, including the Portfolio Optimization Plan costs, (2) percentage changes in revenue, operating income, and diluted earnings per share on an adjusted local currency basis, which eliminate the effects that result from translating its international operations into U.S. dollars and restructuring and other costs, including the Portfolio Optimization Plan costs, and (3) adjusted EBITDA, which excludes restructuring and other costs, including the Portfolio Optimization Plan costs, and non-cash share based compensation expense.
The Company’s corporate expenses, divestiture & other related costs and income, share-based compensation, restructuring and other charges, including operational improvement plan costs and portfolio optimization plan costs, and other costs are included in the “Corporate & Other” category.
The Company’s corporate expenses, share-based compensation, restructuring and other charges, including the Portfolio Optimization Plan costs, and other costs are included in the “Corporate & Other” category.
The lower segment operating income was a result of lower operating income in Personal Care, partially offset by higher operating income in Food & Pharmaceutical Colors. The lower operating income in Personal Care was primarily due to higher raw material and manufacturing and other costs and lower volumes, partially offset by higher selling prices.
The higher operating income in Personal Care was primarily due to higher volumes and selling prices and a favorable product mix. The higher operating income in Food & Pharmaceutical Colors was primarily due to higher volumes and selling prices and a favorable product mix, partially offset by higher raw material and manufacturing and other costs.
The effective tax rates in both 2023 and 2022 were impacted by the release of valuation allowances related to the foreign tax credit carryover and net operating losses, changes in estimates associated with the finalization of prior year foreign and domestic tax items, audit settlements, and mix of foreign earnings.
The effective tax rates in both 2024 and 2023 were impacted by the release of valuation allowances related to net operating losses, changes in estimates associated with the finalization of prior year foreign and domestic tax items, audit settlements, the mix of foreign earnings, and the limited tax deductibility of costs related to the Portfolio Optimization Plan.
Management has recorded valuation allowances to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized. As of December 31, 2023, the Company recorded gross deferred tax assets of $117.4 million with an associated valuation allowance of $34.1 million.
Management has recorded valuation allowances to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized. As of December 31, 2024, the Company recorded gross deferred tax assets of $112.3 million with an associated valuation allowance of $29.7 million.
The increase in expense was primarily due to an increase in the average interest rate and average debt outstanding. 23 Index Income Taxes The effective income tax rate was 28.1% in 2023 and 22.7% in 2022.
The increase in expense was primarily due to an increase in the average interest rate. 23 Index Income Taxes The effective income tax rate was 23.4% in 2024 and 28.1% in 2023.
The lower operating income in Natural Ingredients was primarily due to higher raw material costs, lower volumes, and an unfavorable product mix, partially offset by higher selling prices and lower manufacturing and other costs.
The higher operating income in Flavors, Extracts & Flavor Ingredients was primarily due to lower raw material costs, higher selling prices, higher volumes, and a favorable product mix. The lower operating income in Natural Ingredients was primarily due to higher raw material costs, partially offset by higher volumes and selling prices.
Segment revenue was higher than the prior year primarily due to higher selling prices, partially offset by lower volumes and the unfavorable impact of foreign exchange rates, which decreased segment revenue by approximately 2%. Segment operating income for the Asia Pacific segment was $30.8 million in 2023 and $29.5 million in 2022, an increase of approximately 4%.
Asia Pacific Segment revenue for the Asia Pacific segment was $162.5 million and $146.1 million for 2024 and 2023, respectively, an increase of approximately 11%. Segment revenue was higher than the prior year primarily due to higher volumes and selling prices, partially offset by the unfavorable impact of foreign exchange rates, which decreased segment revenue by approximately 2%.
Selling and administrative expenses as a percent of revenue was further impacted by lower performance-based compensation in 2023. Operating Income Operating income was $155.0 million in 2023 and $196.8 million in 2022. Operating margins were 10.6% in 2023 and 13.7% in 2022.
Selling and administrative expenses as a percent of revenue was further impacted by higher performance-based compensation costs in 2024. Operating Income Operating income was $191.6 million in 2024 and $155.0 million in 2023. Operating margins were 12.3% in 2024 and 10.6% in 2023.
Portfolio optimization plan costs decreased operating margins by approximately 200 basis points in 2023 and divestiture & other related income improved operating margins by approximately 20 basis points in 2022. Additional information on segment results can be found in the Segment Information section. Interest Expense Interest expense was $25.2 million in 2023 and $14.5 million in 2022.
Portfolio Optimization Plan costs decreased operating margins by approximately 40 basis points and 200 basis points in 2024 and 2023, respectively. Additional information on segment results can be found in the Segment Information section. Interest Expense Interest expense was $28.8 million in 2024 and $25.2 million in 2023.
As part of the Portfolio Optimization Plan, in the Flavors & Extracts segment, the Company is evaluating the potential closure of its manufacturing facility in Felinfach, Wales, United Kingdom, the potential closure of its sales office in Granada, Spain, and the potential centralization and elimination of certain selling and administrative positions, with such proposals remaining subject to information and consultation processes in certain countries.
As part of the Portfolio Optimization Plan, in the Flavors & Extracts segment, the Company evaluated the closure of its manufacturing facility in Felinfach, Wales, United Kingdom, the closure of its sales office in Granada, Spain, and the centralization and elimination of certain selling and administrative positions.
Twelve Months Ended December 31, 2023 Total Foreign Exchange Rates Adjustments (1) Adjusted Local Currency Revenue Flavors & Extracts 0.4 % 1.2 % N/A (0.8 %) Color 0.7 % 1.6 % N/A (0.9 %) Asia Pacific 1.7 % (1.8 %) N/A 3.5 % Total Revenue 1.4 % 1.1 % N/A 0.3 % Operating Income Flavors & Extracts (16.7 %) 0.6 % 0.0 % (17.3 %) Color (8.1 %) 1.5 % 0.0 % (9.6 %) Asia Pacific 4.4 % (1.9 %) 0.0 % 6.3 % Corporate & Other 30.6 % 0.0 % 56.3 % (25.7 %) Total Operating Income (21.2 %) 1.0 % (15.4 %) (6.8 %) Diluted Earnings per Share (33.8 %) 0.9 % (20.7 %) (14.0 %) (1) For Operating Income and Diluted Earnings per Share, adjustments consist of divestiture & other related income in 2022 and portfolio optimization plan costs in 2023.
Twelve Months Ended December 31, 2024 Total Foreign Exchange Rates Adjustments (1) Adjusted Local Currency Revenue Flavors & Extracts 7.1 % 0.0 % N/A 7.1 % Color 6.6 % (0.7 %) N/A 7.3 % Asia Pacific 11.2 % (1.8 %) N/A 13.0 % Total Revenue 6.9 % (0.5 %) N/A 7.4 % Operating Income Flavors & Extracts 10.6 % (0.2 %) 0.0 % 10.8 % Color 13.4 % (0.8 %) 0.0 % 14.2 % Asia Pacific 11.9 % (2.2 %) 0.0 % 14.1 % Corporate & Other (13.7 %) 0.0 % (42.4 %) 28.7 % Total Operating Income 23.6 % (1.0 %) 15.3 % 9.3 % Diluted Earnings per Share 33.0 % (1.4 %) 28.5 % 5.9 % Adjusted EBITDA 7.6 % (0.7 %) N/A 8.3 % (1) Adjustments consist of Portfolio Optimization Plan costs.
The Company recognizes related insurance reimbursement when receipt is deemed probable. The Company’s estimate of liabilities and related insurance recoveries may change as further facts and circumstances become known.
The Company’s estimate of liabilities and related insurance recoveries may change as further facts and circumstances become known.
Foreign exchange rates decreased segment operating income by approximately 2%. The increase in segment operating income was a result of higher selling prices, partially offset by higher raw material costs and lower volumes.
The increase in segment operating income was a result of higher volumes and selling prices, partially offset by higher raw material and manufacturing and other costs and the unfavorable impact of foreign exchange rates, which decreased segment operating income by approximately 2%. Segment operating income as a percent of revenue was 21.2% in 2024 and 21.1% in 2023.
The Company’s diluted earnings per share were $2.21 in 2023 and $3.34 in 2022. 2023 results were negatively impacted by $27.8 million ($27.4 million after tax, $0.65 per share) of portfolio optimization plan costs. 2022 results were positively impacted by $2.5 million ($1.9 million after tax, $0.04 per share) of divestiture & other related income.
The Company’s diluted earnings per share were $2.94 in 2024 and $2.21 in 2023. 2024 results were negatively impacted by $6.6 million ($2.5 million after tax, $0.06 per share) of Portfolio Optimization Plan costs. 2023 results were negatively impacted by $27.8 million ($27.4 million after tax, $0.65 per share) of Portfolio Optimization Plan costs.
The Company believes that it has the ability to refinance or repay all of its obligations through a combination of cash flow from operations, issuance of additional notes, and substantial borrowing capacity of approximately $318 million under the Company’s revolving credit facility, which matures in 2026.
The Company believes that it has the ability to refinance or repay all of its obligations through a combination of cash flow from operations, issuance of additional notes, and substantial borrowing capacity of approximately $257 million under the Company’s revolving credit facility, which matures in 2026. 26 Index As a result of our ability to manage the impact of inflation through pricing and other actions, the impact of inflation was not material to the Company’s financial position and its results of operations in 2024.
The Company paid $1.7 million and $21.7 million in 2023 and 2022, respectively, for the acquisition of Endemix Doğal Maddeler A.Ş. and Teknoloji Yatırımları ve Danışmanlık Sanayi ve Ticaret A.Ş. and $1.0 million in 2022 related to a purchase price holdback associated with the acquisition of Flavor Solutions, Inc.
The Company paid $1.7 million in 2023 related to a purchase price holdback associated with the acquisition of Endemix Doğal Maddeler A.Ş. and Teknoloji Yatırımları ve Danışmanlık Sanayi ve Ticaret A.Ş. Cash Flows from Financing Activities Net cash used in financing activities was $81.5 million and $82.0 million in 2024 and 2023, respectively.
Selling and administrative expense as a percent of revenue increased by approximately 170 basis points and decreased by approximately 20 basis points in 2023 and 2022, respectively, as a result of these expenses and income. See Divestitures and Portfolio Optimization Plan below for further information.
Selling and administrative expenses in 2024 and 2023 were increased by Portfolio Optimization Plan costs totaling $5.3 million and $24.7 million, respectively. Selling and administrative expense as a percent of revenue increased by approximately 40 basis points and 170 basis points in 2024 and 2023, respectively, as a result of these costs. See Portfolio Optimization Plan below for further information.
The Company estimates any required write-downs for inventory obsolescence by examining inventories on a quarterly basis to determine if there are any damaged items or slow-moving products in which the carrying values could exceed net realizable value. Inventory write-downs are recorded as the difference between the cost of inventory and its estimated market value.
The Company’s inventories contain a variety of inventory types with varying characteristics that would impact potential inventory obsolescence. The Company estimates any required write-downs for inventory obsolescence by examining inventories on a quarterly basis to determine if there are any damaged items or slow-moving products in which the carrying values could exceed net realizable value.
The decrease in gross margin was primarily due to higher raw material costs, lower volumes, and portfolio optimization plan costs, which decreased gross margin 20 basis points in 2023, partially offset by higher selling prices in 2023. Selling and Administrative Expenses Selling and administrative expense as a percent of revenue was 21.0% in 2023 and 20.3% in 2022.
Gross Profit The Company’s gross margin was 32.6% in 2024 and 31.6% in 2023. The increase in gross margin was primarily due to higher volumes and selling prices, partially offset by higher raw material costs. Selling and Administrative Expenses Selling and administrative expense as a percent of revenue was 20.3% in 2024 and 21.0% in 2023.
For the purposes of the cash flow statement, net changes in debt exclude the impact of foreign exchange rates. The Company has paid uninterrupted quarterly cash dividends since commencing public trading of its stock in 1962. Dividends paid per share were $1.64 in 2023 and 2022. Total dividends paid were $69.2 million and $68.9 million in 2023 and 2022, respectively.
The Company had a net decrease in debt of $7.8 million and $3.5 million in 2024 and 2023, respectively. For the purposes of the cash flow statement, net changes in debt exclude the impact of foreign exchange rates. The Company has paid uninterrupted quarterly cash dividends since commencing public trading of its stock in 1962.
See Note 14, Divestitures , in the Notes to Consolidated Financial Statements included in this report for additional information. Portfolio Optimization Plan During the fourth quarter of 2023, the board of directors of the Company approved a portfolio optimization plan (Portfolio Optimization Plan) to undertake an effort to optimize certain production facilities and improve efficiencies within the Company.
Portfolio Optimization Plan During the fourth quarter of 2023, the Board of Directors of the Company approved a plan to undertake an effort to optimize certain production facilities and improve efficiencies within the Company (Portfolio Optimization Plan).
Adjusted diluted earnings per share, which exclude the divestiture & other related income and the portfolio optimization plan costs, were $2.86 in 2023 and $3.29 in 2022 (see discussion below regarding non-GAAP financial measures). Additional information on the results is included below.
Adjusted diluted earnings per share, which exclude the Portfolio Optimization Plan costs, were $3.00 in 2024 and $2.86 in 2023 (see discussion below regarding non-GAAP financial measures). Additional information on the results is included below. RESULTS OF OPERATIONS 2024 vs. 2023 Revenue Sensient’s revenue was approximately $1.6 billion and $1.5 billion in 2024 and 2023, respectively.
The Company reports all costs associated with the Portfolio Optimization Plan in the Corporate & Other segment. See Note 16, Portfolio Optimization Plan , in the Notes to Consolidated Financial Statements included in this report for additional information.
See Note 15, Portfolio Optimization Plan , in the Notes to Consolidated Financial Statements included in this report for additional information.
The higher operating loss was primarily a result of portfolio optimization plan costs totaling $27.8 million negatively impacting 2023 and divestiture & other related income totaling $2.5 million favorably impacting 2022, partially offset by lower performance-based compensation in 2023. See the Divestitures and Portfolio Optimization Plan sections above for further information.
Corporate & Other The Corporate & Other operating loss was $59.5 million in 2024 and $68.9 million in 2023. The lower operating loss was primarily a result of lower Portfolio Optimization Plan costs, partially offset by higher performance-based compensation costs in 2024. See the Portfolio Optimization Plan section above for further information.
The higher revenue in Food & Pharmaceutical Colors was primarily due to higher selling prices, the acquisition of Endemix Doğal Maddeler A.Ş. , and the favorable impact of foreign exchange rates, partially offset by lower volumes.
The higher segment revenue was a result of higher revenue in Food & Pharmaceutical Colors and Personal Care due to higher volumes and selling prices, partially offset by the unfavorable impact of foreign exchange rates, which decreased segment revenue by approximately 1% .
Foreign exchange rates increased segment operating income by approximately 1%. The lower segment operating income was a result of lower operating income in Natural Ingredients and Flavors, Extracts & Flavor Ingredients.
Flavors & Extracts segment operating income was $97.1 million in 2024 and $87.8 million in 2023, an increase of approximately 11%. Foreign exchange rates had an immaterial impact on segment operating income. The higher segment operating income was a result of higher operating income in Flavors, Extracts & Flavor Ingredients, partially offset by lower operating income in Natural Ingredients.
Estimating liabilities and costs associated with these matters requires the judgment of management, who rely in part on information from Company legal counsel. When it is probable that the Company has incurred a liability associated with claims or pending or threatened litigation matters and the Company’s exposure is reasonably estimable, the Company records a charge against earnings.
When it is probable that the Company has incurred a liability associated with claims or pending or threatened litigation matters and the Company’s exposure is reasonably estimable, the Company records a charge against earnings. The Company recognizes related insurance reimbursement when receipt is deemed probable.
Divestiture & other related income is discussed under “Divestitures” above and Note 14, Divestitures, in the Notes to the Consolidated Financial Statements included in this report. Portfolio optimization plan costs are discussed under “Portfolio Optimization Plan” above and Note 16, Portfolio Optimization Plan, in the Notes to the Consolidated Financial Statements included in this report.
Portfolio Optimization Plan costs are discussed under “Portfolio Optimization Plan” above and Note 15, Portfolio Optimization Plan, in the Notes to the Consolidated Financial Statements included in this report. Note: Earnings per share calculations may not foot due to rounding differences .
Note: Earnings per share calculations may not foot due to rounding differences . The following table summarizes the percentage change in the 2023 results compared to the 2022 results in the respective financial measures.
The following table summarizes the percentage change in the 2024 results compared to the 2023 results in the respective financial measures.
Cash Flows from Investing Activities Net cash used in investing activities was $87.6 million and $98.4 million in 2023 and 2022, respectively. Capital expenditures were $87.9 million in 2023 and $79.3 million in 2022. In 2022, the Company received $2.5 million of proceeds from the divestiture of the yogurt fruit preparations product line.
Cash Flows from Investing Activities Net cash used in investing activities was $59.2 million and $87.6 million in 2024 and 2023, respectively. Capital expenditures were $59.2 million in 2024 and $87.9 million in 2023.
Segment operating income as a percent of revenue was 17.3% and 19.0% for 2023 and 2022, respectively. Asia Pacific Segment revenue for the Asia Pacific segment was $146.1 million and $143.6 million for 2023 and 2022, respectively, an increase of approximately 2%.
Segment operating income as a percent of revenue was 12.2% and 11.8% for 2024 and 2023, respectively. Color Segment revenue for the Color segment was $647.9 million in 2024 and $608.0 million in 2023, an increase of approximately 7%.
The Company recorded non-cash charges of $3.1 million in 2023 in Cost of Products Sold related to the portfolio optimization plan. The charges reduced the carrying value of certain inventories, as they were determined to be excess.
Inventory write-downs are recorded as the difference between the cost of inventory and its estimated market value. The Company recorded non-cash charges of $0.7 million and $3.1 million in 2024 and 2023, respectively, in Cost of Products Sold related to the Portfolio Optimization Plan.
While significant judgment is involved in determining the net realizable value of inventory, the Company believes that inventory is appropriately stated at the lower of cost or net realizable value. Commitments and Contingencies The Company is subject to litigation and other legal proceedings arising in the ordinary course of its businesses or arising under applicable laws and regulations.
While significant judgment is involved in determining the net realizable value of certain inventories with shorter expirations, the Company believes that inventory is appropriately stated at the lower of cost or net realizable value.
The lower revenue in Flavors, Extracts & Flavor Ingredients was primarily due to lower volumes, partially offset by higher selling prices and the favorable impact of foreign exchange rates, which increased segment revenue by approximately 1%. Flavors & Extracts segment operating income was $87.8 million in 2023 and $105.4 million in 2022, a decrease of approximately 17%.
Flavors & Extracts Flavors & Extracts segment revenue was $793.7 million in 2024 and $741.1 million in 2023, an increase of approximately 7%. The higher segment revenue was a result of higher revenue in Natural Ingredients and Flavors, Extracts & Flavor Ingredients due to higher volumes and selling prices. Foreign exchange rates had an immaterial impact on segment revenue.
Color Segment revenue for the Color segment was $608.0 million in 2023 and $604.0 million in 2022, an increase of approximately 1%. Foreign exchange rates increased segment revenue by approximately 2%. The higher segment revenue was a result of higher revenue in Food & Pharmaceutical Colors, partially offset by lower revenue in Personal Care.
Segment operating income for the Color segment was $119.5 million in 2024 and $105.4 million in 2023, an increase of approximately 13%. The higher segment operating income was a result of higher operating income in Personal Care and Food & Pharmaceutical Colors.
The Company’s share repurchase program has no expiration date. These authorizations may be modified, suspended, or discontinued by the Board of Directors at any time. There were no shares of Company stock repurchased in 2023 or 2022. Cash Flows from Operating Activities Net cash provided by operating activities was $169.7 million and $12.1 million in 2023 and 2022, respectively.
In October 2017, the Board of Directors authorized the repurchase of up to three million shares. As of December 31, 2024, 1,732,981 shares were available to be repurchased under the existing authorization. The Company’s share repurchase program has no expiration date. These authorizations may be modified, suspended, or discontinued by the Board of Directors at any time.
In addition, in the Color segment, the Company’s proposals include closing a manufacturing facility in Delta, British Columbia, Canada, closing a sales office in Argentina, and centralizing and eliminating certain production positions as well as potentially eliminating some selling and administrative positions, with such proposals remaining subject to information and consultation processes in certain countries.
In addition, in the Color segment, the Company evaluated the closure of a manufacturing facility in Delta, British Columbia, Canada, the closure of a sales office in Argentina, and centralizing and eliminating certain production positions and selling and administrative positions. The Company reports all costs associated with the Portfolio Optimization Plan in the Corporate & Other segment.
The effective tax rate in 2023 was also impacted by the limited tax deductibility of costs related to the portfolio optimization plan.
The effective tax rate in 2023 was further impacted by the release of a valuation allowance related to the foreign tax credit carryover.
Operating cash flow provided the primary source of funds for operating needs, capital expenditures, and shareholder dividends. The increase in net cash provided by operating activities in 2023 was primarily due to a decrease in the cash used for inventory investments during 2023 compared to 2022 and an increase in cash provided by accounts receivable.
The decrease in net cash provided by operating activities in 2024 was primarily due to a decrease in the cash provided by accounts receivable, partially offset by a decrease in cash used for performance-based compensation payments (which are determined based on prior year performance) made during 2024 compared to 2023.
We continue to expect to manage these impacts in the near term, but persistent, accelerated, or expanded inflationary conditions could exacerbate these challenges and impact our profitability. In October 2017, the Board of Directors authorized the repurchase of up to three million shares. As of December 31, 2023, 1,732,981 shares were available to be repurchased under the existing authorization.
The Company has experienced increased costs for certain inputs, such as raw materials, shipping and logistics, and labor-related costs. We continue to expect to manage these impacts in the near term, but persistent, accelerated, or expanded inflationary conditions could exacerbate these challenges and impact our profitability.
The lower revenue in Personal Care was primarily due to lower volumes, partially offset by higher selling prices and the favorable impact of foreign exchange rates. Segment operating income for the Color segment was $105.4 million in 2023 and $114.6 million in 2022, a decrease of approximately 8%.
These increases were partially offset by the unfavorable impact of foreign exchange rates, which decreased segment operating income by approximately 1%. Segment operating income as a percent of revenue was 18.4% and 17.3% for 2024 and 2023, respectively.